Prognostic influence of clinical and pathological factors in medullary thyroid carcinoma: a study of 53 cases by Brandão, Lenine G. et al.
849
CLINICS 2009;64(9):849-56
CLINICAL SCIENCE
I Surgery Department, Faculdade de Medicina da Universidade de São 
Paulo - São Paulo/SP, Brazil.
II Head and Neck Department, Brazilian Institute of Cancer Control - São 
Paulo/SP, Brazil.
Email: bgcavalheiro@yahoo.com.br
Tel: 55 11 9689.2529
Received for publication on April 27, 2009
Accepted for publication on June 24, 2009
PROGNOSTIC INFLUENCE OF CLINICAL AND 
PATHOLOGICAL FACTORS IN MEDULLARY THYROID 
CARCINOMA: A STUDY OF 53 CASES
Lenine G. Brandão,I Beatriz G. Cavalheiro,II Consuelo R. JunqueiraI 
 
doi: 10.1590/S1807-59322009000900005
Brandão LG, Cavalheiro BG, Junqueira CR. Prognostic influence of clinical and pathological factors in medullary thyroid 
carcinoma: a study of 53 cases. Clinics. 2009;64(9):849-56.
OBJECTIVES AND INTRODUCTION: Medullary thyroid carcinoma, a neoplasia of intermediate prognosis and differentia-
tion, does not always respond predictably to known treatments. This study aimed to correlate the clinical progression of surgically 
treated patients with clinical and pathological data. 
METHODS: A total of 53 patients were followed for 75 months (mean average) in tertiary-care hospital. The clinical status of 
patients at the end of the study period was characterized to determine correlations with a range of disease aspects. A value of p < 
0.05 was considered statistically significant. 
RESULTS: Twenty-two patients (41.5%) were alive and disease-free at the end of the follow-up period; twenty-three patients 
(43.4%) had persistent disease; and eight patients (15.1%) had recurrent disease. Four patients (7.6%) died from medullary thyroid 
carcinoma with clinical and/or imaging evidence of neoplasia. The following aspects demonstrated statistically significant correla-
tions with the final medical condition: positive initial cervical examination (p = 0.002); neoplastic extensions to the thyroid capsule 
(p = 0.004) and adjacent tissues (p = 0.034); cervical lymph node metastases (p < 0.001); diameter of neoplasia (p = 0.018); TNM 
(tumor, node and metastasis) Stage (p = 0.001) and evidence of distant and/or cervical diseases in the absence of a cure (p = 0.011). 
Through logistic regression, the presence of cervical lymph node metastases was considered an independent variable (p < 0.001).
CONCLUSIONS: Clinical and pathological aspects of patients with surgically treated medullary thyroid carcinomas are predictors 
of disease progression. Specifically, even treated cervical lymph node metastases are significantly correlated with disease progression.
KEYWORDS: Medullary thyroid carcinoma; Thyroid neoplasms; Multiple endocrine neoplasia; Prognosis; Cervical lymph node.
INTRODUCTION
Medullary thyroid carcinoma (MTC) is responsible 
for 3 to 15% of malignant thyroid tumors.1-6 It is derived 
from C cells, which produce amines and peptides, such 
as calcitonin (CT). CT is used as a specific diagnostic and 
prognostic marker for MTC and has been identified in both 
the tumor specimens and serum of patients with MTC.4 
Carcinoembrionic antigen (CEA) may also be a useful 
marker for MTC, but it is less specific and less sensitive 
than CT.7 
MTC presents peculiar characteristics in various 
clinical presentations. Most MTC cases are sporadic. 
Others are inherited from germline mutations of the RET 
proto-oncogene and constitute familial presentations of the 
disease. In the inherited clinical presentation its transmission 
is autosomal dominant, with high penetrance, variable 
expressivity, and age dependence.8 Patients may be grouped 
into at least four distinct categories: MTC associated with 
MEN2A (multiple endocrine neoplasia type 2A); MTC 
associated with a subtype of MEN2A related to the presence 
of cutaneous injuries of lichen amyloidosis; MTC associated 
with MEN2B (MEN type 2B); and the isolated familial 
MTC, which lacks other related endocrinopathies. 8,9
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Advances in our understanding of the genetics of 
MTC have provided better accuracy in determining its 
clinical presentations, and investigational programs have 
been developed for the pre-symptomatic diagnosis of the 
familial form of the disease.8 Several RET proto-oncogene 
germline mutations have been reported to activate the RET 
protein receptor and are considered to be related to familial 
presentations of MTC. Nonetheless, little is understood 
regarding the biological aspects of MTC. Genotype-
phenotype correlations have also been described since 
specific mutations of the RET proto-oncogene may lead to 
particular clinical manifestations of neoplasia. 9-14 
Surgery is currently the only effective treatment 
available,15-17 and the success of treatment depends strongly 
upon the clinical stage of the patient and the appropriateness 
of initial surgery. In addition to clinical presentation, 
tumor behavior and prognosis of patients with MTC are 
also varied. A tendency toward early metastatic lymph 
node dissemination has been observed.16,17 However, 
indolent cases can contrast with very aggressive ones.6 
Long-term progression may be satisfactory for patients 
with high serum CT levels after surgery, and the lack 
of demonstrable metastatic or residual disease is not an 
uncommon situation.9,14,18-23 Some patients with evident 
metastatic disease may live for years, as well.9 Many studies 
have already attempted to determine predictive factors for 
prognostic impairment in patients with properly treated 
MTC. The results obtained have not been uniform, possibly 
because of the heterogeneity of patients. However, MTC is 
undoubtedly a disease that has the potential to be fatal.
In this study, we have identified clinical and pathological 
factors affecting clinical progression in surgically treated 
MTC patients.
METHODS AND MATERIALS
Patients
This study was approved by the ethics committee for 
human studies (CAPPESQ – number 16.416/02 – 12 June 
2002). Fifty-three patients followed by the Head and Neck 
Surgery and Endocrinology Departments of the Faculdade 
de Medicina da Universidade de São Paulo in Brazil, were 
selected for retrospective analysis. All had been diagnosed 
with MTC and had undergone surgery as their initial therapy. 
Only patients whose clinical and pathological data were 
found in their medical records were included in the study. The 
median age of patients at the time of admission was 36 years 
(range, 9-69 years). Thirty-five patients (66.0%) were women. 
Thirty-four patients (64.1%) were considered sporadic; 
eighteen patients (34.0%) had MTC associated with MEN2A; 
and one patient (1.9%) had MTC associated with MEN2B. 
None had the isolated familial presentation of the neoplasia. 
After surgery, cure was defined as a drop in CT serum 
titer to or below the upper limit of the laboratory reference 
range; recurrence was defined as an increase in CT serum 
titer levels at least six months after the determination of 
cure. Either maintenance of CT serum titer levels above 
the reference limit or an increase above reference limits 
less than six months after an earlier reduction indicate 
neoplastic persistence.24 Biochemical disease was defined 
in those patients whose serum CT levels remained high with 
no clinical and/or imaging evidence of cervical neoplasia 
or metastases. Relative values of serum basal CT and CEA 
were analyzed, and the number of increases in relation to 
the maximum reference value was examined. The maximum 
number observed during the progression of each patient was 
used for the analysis. Out-patient visits, accompanied by 
serum measurement of calcitonin and CEA, occurred every 
two months for the first year and biannually thereafter. At the 
time of the first postoperative ambulatory visit, conducted 
up to three weeks after surgery, patients were classified as 
cured or with persistent disease. CT and CEA measurements, 
however, were not always available in our laboratories, as 
patients compliance with ambulatory visits and laboratory 
controls were not constant. 
Based on their medical condition during their last 
ambulatory visit, patients were classified as cured or not 
cured, which included those patients who were dead because 
of disease. Clinical progression was compared with clinical 
and pathological aspects. Four patient deaths in the whole 
group were attributed to MTC and they occurred at 14, 
16, 19, and 88 months of clinical follow-up. Patients were 
followed for a median of 55 months (mean of 75 months; 
range, 4-225 months) from June of 1 982 to February 
of 2 006. The patient who was followed for only four 
months was alive and with biochemical disease at the last 
ambulatory visit. 
Statistical Analysis
Percentile and absolute distributions were obtained 
for nominal variables. For numerical variables, inferential 
statistical measures were acquired through the Chi-Square 
test of independence and Fisher’s exact test. Logistic 
regression was used for multivariate analysis. Odds ratios 
and confidence interval values were calculated through 
the association of independent and dependent variables in 
a bivariate analysis. Values of p < 0.05 were considered 
statistically significant. SPSS, version 13.0 (Statistical 
Package for the Social Sciences, Chicago, Il, USA) was used 
for the statistical analysis.
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RESULTS
Twenty-nine patients (54.7%) were considered cured 
after the initial surgical treatment. Eight patients progressed 
with neoplastic recurrences. The 32 patients who were 
not cured were grouped as follows: 18 patients had only 
biochemical disease (56.25%); 7 patients had distant 
metastatic and cervical disease (21.9%); 6 patients had only 
cervical disease (18.75%); and 1 patient had only distant 
metastatic disease (3.1%). 
For the 35 patients whose serum doses of calcitonin 
during the preoperative or immediate postoperative periods 
were measured, the values were calculated as a mean of 
151.7 fold greater than the maximum laboratory reference 
value and a median of 17.66 fold greater than the maximum 
laboratory reference value (SD ±412.15 fold). Serum values 
of CEA were calculated at a mean of 10.27 fold greater than 
the maximum laboratory reference value and a median of 
2.65 fold greater than the maximum laboratory reference 
value (SD ±15.12 fold). 
Clinical and pathological variables were correlated 
with the patient being either cured or not cured as the final 
medical conditions. Variables that demonstrated statistically 
significant correlations are as follows: evidence of primary 
neoplasia and/or lymph node basins on initial cervical 
examination (p = 0.002); neoplastic extension through 
the thyroid capsule (p = 0.004) and to tissues adjacent to 
the gland (p = 0.034); diameter of neoplasia (p = 0.018); 
presence of cervical lymph node metastases (p < 0.001); 
TNM (tumor, node, metastasis) Cancer Stage25* (p < 0.001) 
(Table 1); and presentation of disease among those who 
were not cured (p = 0.011) (Table 2). The presence of distant 
metastasis on admission did not demonstrate a statistically 
significant association with any of the defined final medical 
conditions. However, there was one patient for this variable 
(in costal arch), who died of the disease. Four patients died 
from MTC; all of these patients presented with clinical and/
or imaging evidence of neoplasia. 
Through logistic regression, only the presence of lymph 
node metastases was considered to be an independent 
variable (p < 0.001) (Table 3). Patients without cervical 
lymph node metastases were 24 times more likely to achieve 
a cure than those with regional disease.
Positive initial cervical examination (p = 0.013); 
neoplastic extension through the tissues adjacent to the 
thyroid (p = 0.038); presence of cervical lymph node 
metastases (p < 0.001); and TNM stage (p < 0.001) were 
correlated with tumor persistence after the initial operation 
(as defined in “methods”). However, through logistic 
regression, only the presence of lymph nodes metastases was 
considered an independent variable (p < 0.001). 
DISCUSSION
Cervical lymph node metastases and TNM stage were 
characterized as the most important prognostic factors 
for patients operated on for MTC, and they are correlated 
variables. Cervical lymph node metastases were identified 
in all of the patients who died, while only 2 of 26 patients 
with cervical metastatic impairment (7.7%) were cured. 
Among those patients who remained alive with the disease, 
more than 70% had cervical metastases at the initial surgical 
treatment. Of the subjects, 79% who progressed with clinical 
and/or imaging evidence of local and/or distant neoplasias 
had cervical metastases upon the initial staging. Cervical 
metastatic neoplasia has previously been associated with 
tumor stage,26 increased risk of neoplastic progression, and 
prognostic impairment.6,14,15,18,23,27-29 
Almost half of patients studied were classified as stage 
IV using the TNM Stage System, and the predominance 
of patients admitted with advanced MTC is not exclusive 
to our case studies.14,15,27 In our analysis, only stage IV 
patients died. Seventeen of twenty-two stage I or II patients 
(77.3%) were alive and disease-free at the end of the follow-
up periods. Furthermore, 25 of 32 patients whose tumors 
persisted or recurred (78.1%) had been classified as stages 
III or IV. Consulted authors1,14,18,26,30,31 also considered TNM 
stage a relevant prognostic factor.
Cervical lymph node metastases were identified in 20 of 
33 patients with neoplasias of 15 mm in diameter or larger 
(60.6%) and in 6 of 18 patients whose primary tumors were 
smaller than 15 mm (33.3%). Therefore, only six of twenty-
six patients with cervical lymph node metastases (23.1%) 
had primary tumors smaller than 15 mm. Among the patients 
who died, three had been treated for primary neoplasias 
larger than 30 mm, and one was treated for a neoplasia of 
15 mm; all four already had cervical metastatic disease. 
Other investigators have also observed correlations between 
primary tumor dimensions and disease progression.14,15,28 
Patients with palpable MTCs frequently present with 
cervical lymph node metastases.1,20 Forty patients (75.5%) 
were identified through positive initial cervical physical 
examinations, a negative prognostic factor, as also observed 
by Kebebew et al.18 All patients whose neoplasias persisted 
* Tumor size => T1: < 2 cm; T2: > 2 cm and < 4 cm; T3: > 4 cm or minimal extrathyroid extension; T4a: extrathyroid extension (resectable); T4b: 
unresectable extension. Lymph node => N0: no regional lymph node metastasis; N1a: metastasis to level VI; N1b: metastasis to unilateral, bilateral or 
contralateral cervical or superior mediastinal lymph nodes. Distant metastasis => M0: absent; M1: present. Stages => I: T1N0M0; II: T2N0M0; III: 
T3N0M0, T1-2-3N1aM0; IVA: T4a any N M0, T1-2-3N1bM0; IVB: T4b any N M0; IVC: any T any N M1.
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Table 1 - Correlation of final medical condition with clinical and pathological variables 
VARIABLE
FINAL MEDICAL CONDITION
p valueCured Not Cured TOTAL
n % n % n %
Age group (years)
Up to 20 6 50.0 6 50.0 12 100.0 (1) 0.603
21 to 40 5 31.3 11 68.8 16 100.0
41 or over 10 40.0 15 60.0 25 100.0
Sex
Male 9 50.0 9 50.0 18 100.0 (2) 0.268
Female 12 34.3 23 65.7 35 100.0
Diagnosis through screening
Yes 7 46.7 8 53.3 15 100.0 (2) 0.510
No 14 36.8 24 63.2 38 100.0
Positive initial cervical examination
Yes 11 27.5 29 72.5 40 100.0 (2) 0.002*
No 10 76.9 3 23.1 13 100.0
Systemic symptoms
Yes 3 33.3 6 66.7 9 100.0 (1) 1.000
No 18 40.9 26 59.1 44 100.0
Thyroid capsule invasion
Yes 2 11.8 15 88.2 17 100.0 (2) 0.004*
No 19 52.8 17 47.2 36 100.0
Adjacent extension
Yes - - 7 100.0 7 100.0 (1) 0.034*
No 21 45.7 25 54.3 46 100.0
Tumor diameter (mm)†
< 15 11 61.1 7 38.9 18 100.0 (1) 0.018*
≥ 15 9 27.3 24 72.7 33 100.0
TNM stage †
I or II 17 77.3 5 22.7 22 100.0 (1) < 0.001*
III 1 14.3 6 85.7 7 100.0
IV 2 9.1 20 90.9 22 100.0
• Cervical lymph node metastases
Yes 2 7.7 24 92.3 26 100.0 (2) < 0.001*
No 19 70.4 8 29.6 27 100.0
• Clinical presentation 
Sporadic 8 42.1 11 57.9 19 100.0 (2) 0.782
Familial 13 38.2 21 61.8 34 100.0
Initial calcitonin levels‡
Up to 10x 6 54.5 5 45.5 11 100.0 (1) 0.280
>10x to 30x 1 12.5 7 87.5 8 100.0
>30x to 100x 2 33.3 4 66.7 6 100.0
> 100x 2 22.2 7 77.8 9 100.0
High initial CEA levels ƒ
Yes 4 28.6 10 71.4 14 100.0 (2) 1.000
No 3 37.5 5 62.5 8 100.0
(1)
 By Fisher’s exact test. (2)  By Chi-Square test. (*) Significant association with p less than 0.05. (†) 51 patients. (‡) The number of increases in relation to 
the maximum laboratory reference value (relative values). For 34 patients. (ƒ) 22 patients.
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or recurred and who progressed with imaging and/or 
clinically evident active disease had also demonstrated 
clinical evidence of MTC on admission. 
Neoplastic extensions to the thyroid capsule and to 
tissues adjacent to the thyroid correlated significantly with 
the final medical condition. No patient with neoplastic 
extension to tissues adjacent to the thyroid was cured. 
Among the 17 patients whose tumors affected the thyroid 
capsule, 13 also had cervical lymph node metastases, 
regardless of tumor size. Infiltration of tissues adjacent to 
the thyroid has previously been associated with a major risk 
of disease progression and death.23,26-28,32 
Advanced disease was not exclusive to older patients, 
and statistically significant correlations were not observed 
between age groups and progressions, as also reported 
by Weber et al.27 This observation is contrary to other 
studies,1,6,14,15,18,22,28,30,31,33,34,35 which have stated that older 
patients generally had worse prognoses than younger 
ones. Statistical significance was also not obtained when 
sex was compared to clinical progression, as observed by 
other authors.22,27 The proportion of males with cervical 
metastases (44.4%, compared to 51.4% among women) and 
the proportion of stage IV men (50.0%, compared to 37.1% 
among women) were not significantly different from figures 
for females. Nevertheless, in the examined studies, female 
patients showed higher survival rates,1,6,14,15,18,30,34 even when 
compared to men affected by neoplasias of similar stages,1 
and a lower risk of disease progression.28 
Although the presence of systemic symptoms was not 
characterized as a prognostic factor, of the nine patients 
who reported these symptoms (diarrhea and/or weight 
loss), six had already had cervical lymph node metastases. 
Furthermore, there was only one patient with distant 
metastasis on admission. Three of the four patients who 
died reported systemic symptoms on admission. The global 
survival rate was already characterized as significantly 
lower among patients with diarrhea;121 in another study,18 
all sporadic patients who reported systemic symptoms were 
classified as stage IV and died during the follow-up period.
Participation of the clinical presentation of MTC in 
the final medical conditions was not observed because the 
proportion of patients with cervical lymph node metastases 
and stage IV patients were also rather similar. Studies131,14,18,31 
emphasized prognostic differences related to the clinical 
presentations of MTC, favoring those patients associated 
with MEN2A. Nonetheless, Hyer et al.15 and Ellenhorn et 
al.22 did not observe distinct progressions among sporadic 
and familial patients with cervical metastatic disease. 
Clinical disease presentation was also not characterized as a 
prognostic factor in a multivariate analysis led by Weber et 
al.27 It is possible that the opportunity for early diagnosis of 
MTC afforded by MEN2A provides a prognostic advantage 
to patients over other MTC types. However, early diagnosis 
did not occur at a significant rate among our cases, including 
Table 2 - Correlation of final medical condition with progression presentation (patients not cured)
VARIABLE
MEDICAL CONDITION
(1)p-valueAWD DBD TOTAL
n % n % n %
Only cervical disease 5 83.3 1 16.7 6 100.0
Only distant metastasis - - 1 100.0 1 100.0
Cervical disease and distant metastasis 5 71.4 2 28.6 7 100.0 0.011*
Biochemical disease (2) 17 100.0 - - 17 100.0
TOTAL(3) 27 87.1 4 12.9 31 100.0
Condition of patient: AWD = alive with disease at the end of the follow-up; DBD = dead because of disease. (1) By Fisher’s exact test. - Nil occurrences. 
(*)
 Significant association with p less than 0.05. (2) Without evidence of local or distant disease, despite the increase in calcitonin. (3) Alive without disease 
were excluded
Table 3 - Logistic regression for cure (final medical condition)
VARIABLE Odds ratio and Confidence Interval (95.0%) p value 
Bivariate study Adjusted
• Lymph node metastases
Yes 1.00 1.00
No 28.50 (5.41 - 150.23) 24.42 (4.33 -137.76) p < 0.001*
(*) Significant association with p less than 0.05
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those patients who were diagnosed through screenings.
The presence of distant metastasis at MTC diagnosis was 
reported in only one patient, and his death was attributed to 
neoplasia. The presence of distant metastasis at diagnosis 
also has prognostic relevance in the experience of other 
authors.14,15,28,29 
Therapeutic modalities were not analyzed because the 
variety of surgical approaches in the presence of very distinct 
clinical features did not allow for accurate analysis of their 
relationship to the prognosis. All patients were submitted 
to total thyroidectomy, except for two whose tumors were 
inoperable. Only nine patients were not submitted to 
any kind of cervical dissection, including those two with 
inoperable tumors. None of the 32 patients, whose tumors 
persisted or recurred, were subsequently cured, despite 
complementary operations (seven patients) or adjuvant 
therapies (eight patients). 
The presence of active disease was considered a 
prognostic factor for death or survival. The four patients who 
died because of the disease had a progressed disease with 
clinical and/or imaging evidence of cervical and/or distant 
neoplasia. It has already been observed that 70% of deaths 
occur during the first five years of diagnosis 35 as a result of 
locally aggressive neoplasias.21,28
Basal calcitonemia and serum CEA levels upon diagnosis 
of MTC were very diverse, and their values indicated 
considerable variability, mainly among patients with high 
levels of the markers. In the course of the studied clinical 
progression, 16 patients progressed with high levels of 
CT, up to 100 times the upper laboratory limits, and 14 
maintained values over 100 times the upper laboratory limits. 
Of these 14 patients, 10 showed clinical and/or imaging 
evidence of cervical and/or distant disease, including those 
who died. A significant tendency towards high serum titers 
of basal CT in patients with advanced tumors was observed 
previously.1 Some researchers22,23 have not observed a 
correlation between serum CT levels and prognosis, while 
other authors36,37 have identified pre- and postoperative 
serum CT levels to be predictive elements of progression 
and have observed that all patients not cured had higher 
preoperative basal serum CT levels. 
Of the 22 patients whose initial serum CEA levels were 
measured, eight were within normal limits despite the 
presence of MTC. Of the 26 patients not cured in whom 
the marker was measured, 11 patients who progressed to 
active disease had low serum CEA titers, thus, rendering 
the negative predictive value of this marker low. Modigliani 
et al.14 considered normal preoperative serum CEA values 
as predictors of cure and related them to pathological 
stages. Others38 correlated serum CEA levels with success 
of the initial surgery, tumor dimensions, and presence of 
metastases.
In previous research,39,40 we observed a correlation 
between prognosis and the immunohistochemical 
expressions of metalloproteinases—enzymes related to the 
extracellular matrix and basement membrane degradation—
in MTC surgical specimens. However, statistical parameters, 
such as sensitivity and specificity, showed that the presence 
of cervical lymph node metastases and TNM stage were the 
major variables. 
At the end of the follow-up period, 22 patients (41.5%) 
were alive and without disease, 27 (50.9%) were alive with 
disease, and 4 (7.6%) had died because of MTC. These data 
are compatible with the findings of other authors.14,18,19,22,27,31
CONCLUSION
The current study demonstrated that specific factors 
that determine the prognosis of individuals with MTC 
(positive initial cervical physical examination, neoplastic 
extension to thyroid capsule and adjacent tissues, diameter 
of the neoplasia, cervical lymph node metastases, TNM 
stage, and evidence of distant and/or cervical diseases in 
case of absence of cure) should be observed after diagnosis 
and surgery, so each case can be treated with the requisite 
attention and concern.
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